Medipharm Labs and TerrAscend Corp Enter $27 Million Cannabis Distillate Agreement

Medipharm Labs (TSX: LABS) and TerrAscend Corp (CSE: TER) announced a significant transaction this morning, wherein Medipharm will supply a minimum of $27 million in cannabis distillate to TerrAscend over the next two years. The contract has the potential to expand to $192 million under certain conditions.

The cannabis distillate will be utilized by TerrAscend to produce branded products for the “rec 2.0” market, which includes items such as vapes and other concentrates. A series of branded products are expected to be released by TerrAscend Canada this fall.

The base agreement will see TerrAscend purchase a minimum of $27 million in cannabis distillate from Medipharm Labs in a 24 month period ending September 2021, with an option to acquire up to $105 million in distillate subject to availability of product. A one year extension also exists for the agreement, which has a minimum purchase value of $10 million in distillate. The extension comes with a right of first refusal for an additional $51 million in cannabis concentrate, subject to availability, for TerrAscend Corp.

The result of the numerous optional extensions and additional purchases is a contract that may be up to $192 million in value. However, the minimum purchases result in a contract that is $27 million in size as a base line.

The deal is the second significant supply agreement for Medipharm Labs announced as of late, following last weeks announcement of a second manufacturing agreement with that of Cronos Group.

Medipharm Labs closed yesterdays session at $4.77 on the Toronto Stock Exchange.


Information for this briefing was found via Sedar, Medipharm Labs and TerrAscend Corp. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

When 4% of Global Copper Disappears Overnight | David Gower – Emerita Resources

Mining M&A: Gold X2 Acquires Kesselrun Resources

They Said Oil Was Dead. They Were Wrong. | Michael Judson – Record Resources

Recommended

Steadright Secures Two Additional Exploration Licenses For Flagship Project

First Majestic Posts Record Quarterly Silver Production In Q3

Related News

Medipharm Labs Sees PI Financial, Mackie Research Drop Estimates, Price Targets

Medipharm Labs (TSX: LABS) reported Q1 2020 results on Thursday, June 18, which showed it’s...

Friday, June 19, 2020, 02:55:31 PM

Hexo Has Filed A $35 Million Counterclaim Against Medipharm Labs

It appears that Hexo Corp (TSX: HEXO) (NYSE: HEXO) has filed a counterclaim against Medipharm...

Thursday, June 18, 2020, 11:48:39 AM

Harvest Moon: Valens Company VS Medipharm Labs – Share Price Indicators

Of the 100 companies in the BI Global Cannabis Competitive Peers index tracked in 2019,...

Sunday, June 21, 2020, 05:00:00 PM

TerrAscend And Canopy Rivers Forced To Change Loan Terms By TSX

It appears that the Toronto Stock Exchange has begun to slowly crack down on investments...

Wednesday, February 5, 2020, 09:04:27 AM

Medipharm Labs Reports Q4 Revenues Of $6.1 Million, Net Loss Of $30.9 Million

Medipharm Labs (TSX: LABS) this morning reported its fourth quarter financial results for 2020. Revenues...

Wednesday, March 31, 2021, 07:47:27 AM